Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Songling Xuemaikang Capsules for Cerebral Small Vessel Disease
NCT07271732Not yet recruiting
- Sponsor
- Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine
- Start
- Dec 2025
- Primary completion
- Dec 2026
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of songling xuemaikang in Cerebral Small Vessel Disease (CSVD) and hypertension (HTN) (2 arms), sponsored by Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine. Primary endpoint: Volume of white matter hyperintensities at 1 year. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
songling xuemaikang
03
Conditions
Cerebral Small Vessel Disease (CSVD)hypertension (HTN)
Beyond the preview
Go deeper on NCT07271732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07271732.